SAN FRANCISCO and SUZHOU, China, Dec. 9, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic,...
Hence then, the article about innovent announces first participant dosed in a phase 1 clinical trial of ibi3011 a recombinant anti human interleukin 1 receptor accessory protein monoclonal antibody was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Innovent Announces First Participant Dosed in a Phase 1 Clinical Trial of IBI3011, a Recombinant Anti-Human Interleukin 1 Receptor Accessory Protein Monoclonal Antibody )
Also on site :
- 2026 Novel Perfect for ‘Final Destination 3’ Fans Has Been Named One of the Best Thrillers of the Year by Amazon
- Sosie Bacon, the Daughter of Kevin Bacon and Kyra Sedgwick, Is a Red Carpet Stunner Who Resembles Her Mom
- Walmart's $18 2-Drawer Dresser Is 'Great for Small Spaces' and Comes in 4 Colors